Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission.
HIV-1, herpes simplex virus type 2 (HSV-2), and human papillomavirus (HPV), among other sexually transmitted infections, represent a major burden for global health. Initial insights into the mucosal transmission of these viral pathogens have raised optimism with regard to the rapid generation of protective vaccines. Nevertheless, setbacks for HIV-1 and HSV-2 vaccines have seriously challenged the initial enthusiasm. Recently, two new vaccines that efficiently prevented HPV infection have renewed the hope that vaccinal prevention of viral mucosal sexually transmitted infections is possible. HIV-1 and HSV-2 differ from HPV, and each virus needs to be tackled with a distinct approach. However, vaccines are not the only possible answer. Topically applied agents (microbicides) are an attractive alternative in the prevention of HIV-1 and HSV-2 mucosal transmission. Progress in understanding the mechanisms of genital transmission of HIV-1 and HSV-2 is required for successful vaccine or microbicide candidates to emerge from current approaches.
Nikolic
Damjan S
DS
Department of Dermatology and Venereology, University Hospital and Medical School of Geneva, Geneva, Switzerland.
Piguet
Vincent
V
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology; D003140:Communicable Disease Control; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D015497:HIV-1 / Q000378:metabolism*; D006558:Herpes Genitalis / Q000517:prevention & control* / Q000635:transmission; D018258:Herpesvirus 2, Human / Q000378:metabolism*; D006801:Humans; D051379:Mice; D008954:Models, Biological; D009092:Mucous Membrane / Q000821:virology*; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000635:transmission; D012749:Sexually Transmitted Diseases / Q000517:prevention & control / Q000635:transmission; D014612:Vaccines / Q000378:metabolism
D000890:Anti-Infective Agents; D014612:Vaccines